908 Devices Partners with Getinge to Advance Bioprocessing Automation in Biopharma
- 908 Devices partners with Getinge to automate bioprocessing workflows, integrating MAVEN system with advanced bioreactors for real-time monitoring.
- The MAVEN system allows continuous analysis of glucose and lactate levels, enhancing cell culture monitoring and drug development efficiency.
- This collaboration aims to optimize bioprocessing conditions and improve productivity in the biopharmaceutical industry through advanced automation tools.
908 Devices and Getinge Forge Partnership to Revolutionize Bioprocessing Automation
908 Devices Inc. announces an innovative collaboration with Getinge aimed at transforming bioprocessing workflows. The partnership integrates Getinge’s advanced bioreactors with 908 Devices’ MAVEN system, a cutting-edge technology designed to automate the monitoring and control of glucose and lactate levels in cell cultures. This integration allows for continuous, real-time analysis without the need for manual sampling, a crucial advancement for biopharmaceutical research and development. By streamlining the process, the collaboration addresses the growing need for precise monitoring of cell culture conditions, ultimately enhancing productivity and accelerating time to market for new drugs.
The MAVEN system's on-line monitoring capability ensures that the volume of bioreactors remains unaffected while allowing scientists to maintain optimal nutrient levels, even at low concentrations. This feature is particularly significant in biopharmaceutical applications, where minute variations in metabolite levels can drastically impact the yield and quality of biologics. Timo Keijzer, Director of Product Marketing at Getinge, underscores the partnership’s potential to improve laboratory workflows by providing continuous visibility into concentration changes, enabling timely adjustments to control strategies. The MAVEN system can manage measurements from two bioreactors simultaneously, leveraging Getinge’s advanced controllers to establish effective control loops.
The collaboration marks a significant step towards enhancing bioprocess automation in the biopharmaceutical sector. Christopher D. Brown, Chief Product Officer and Co-founder of 908 Devices, emphasizes the mutual commitment to empowering biopharma clients with modern automation tools that foster a deeper understanding of processes and expedite development workflows. The MAVEN device is designed to integrate seamlessly with Getinge’s Livit Flex controller, creating a robust platform for optimizing bioprocessing conditions. This partnership not only signifies a leap forward in technology but also highlights the critical role of real-time monitoring and control in the evolving landscape of biopharmaceutical product development.
In addition to this collaboration, Getinge’s global footprint, with approximately 12,000 employees and products available in over 135 countries, positions it as a leader in enhancing clinical outcomes across various medical fields. The combined expertise of 908 Devices and Getinge is set to redefine the standards for bioprocessing, ultimately benefiting the biopharmaceutical industry by improving efficiency and enabling quicker access to vital therapies.